Chugai stops Gym329 obesity development, returns license and resumes SMA work
Reuters says Chugai Pharmaceutical Co Ltd is discontinuing development of Gym329 (Emugrobart) for obesity, returning the license and resuming development for SMA.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.